Trial Profile
Correlation of Functional and Structural Outcomes With Serum Antibody Profiles in Patients With Neovascular Age-related Macular Degeneration Treated With Ranibizumab and Healthy Subjects: A Prospective, Controlled Monocenter Trial
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Ranibizumab (Primary)
- Indications Age-related macular degeneration
- Focus Therapeutic Use
- Acronyms CAPTAIN
- 30 Nov 2017 Status changed from recruiting to completed.
- 16 Aug 2016 Status changed from not yet recruiting to recruiting.
- 21 Jul 2016 New trial record